Trial site
Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu Sp z o o
Sosnowiec, 41 200, PolandEU-13 widening countryNot linked to an institution yet
- 19running trials
- 9closed trials
The trials here
What the 28 trials at this site are about, from their registry records.
- Phase
- Phase 215 trials
- Phase 312 trials
- Phase 2/31 trial
- Status
- Completed9 trials
- Active, not recruiting8 trials
- Recruiting8 trials
- Not yet recruiting3 trials
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Almirall, S.A.2 trials
- MoonLake Immunotherapeutics AG2 trials
- Pfizer2 trials
- UCB Biopharma SRL2 trials
- and 17 more
Running trials
Not yet recruiting
A study in young people and adults to learn about the medicine ritlecitinib for treatment of patchy hair loss, known by the medical term as moderate alopecia areata
2026-526355-62-00· Phase 3· Pfizer Inc.· Source
Not yet recruiting
A study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00· Phase 2· Enveda Therapeutics Inc.· Source
Recruiting
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis
NCT07660835· Phase 2· Galderma R&D· Source
Recruiting
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
NCT07547813· Phase 2· Almirall, S.A.· Source
Active, not recruiting
A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis
2025-522113-35-00· Phase 2· Triveni Bio Inc.· Source
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975· Phase 2· Navigator Medicines, Inc.· Source
Active, not recruiting
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· Phase 2· UCB Biopharma SRL· Source
Active, not recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390· Phase 2· Pfizer· Source
Recruiting
A Study of LAD191 in Adults With Hidradenitis Suppurativa
NCT07151937· Phase 2· Almirall, S.A.· Source
Active, not recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· Phase 2· Apogee Therapeutics Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Inmagene LLC· Source
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Recruiting
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT06668181· Phase 3· UCB Biopharma SRL· Source
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
NCT06100744· Phase 3· AbbVie· Source
Active, not recruiting
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948· Phase 2· Apogee Therapeutics, Inc.· Source
Active, not recruiting
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches
2023-504447-14-00· Phase 2/3· Sun Pharmaceutical Industries Limited· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error